Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II niraparib + anlotinib in recurrent small cell lung cancer
ChiCTR2100046269Phase 2Recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and anlotinib in small cell lung cancer (SCLC), sponsored by Jilin Provincial Cancer Hospital. Primary endpoint: Overall response rate. Started Jun 2021; status: recruiting.
02
Drugs
niraparibanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100046269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046269.